Quick Facts

• Infectious Ocular Conditions: Used to treat various inflammatory and infectious diseases of the anterior segment of the eye caused by susceptible microorganisms.
• Prophylactic Use: Employed for the prevention of infectious complications during the preoperative and postoperative periods in ophthalmic surgery.

---

What Офтамирин Treats: Main Uses and Benefits

Офтамирин is a topical antiseptic treatment used primarily in ophthalmology to manage conditions affecting the surface and anterior structures of the eye. Its use is focused on addressing infections and inflammatory processes triggered by bacteria, fungi, or other pathogens. The therapeutic goal is to eliminate infectious agents and support the resolution of inflammation on the ocular surface.

The medication is indicated for the treatment of acute and chronic conditions such as conjunctivitis, keratitis, and blepharoconjunctivitis. By inhibiting the growth of microorganisms, it helps to reduce the symptoms associated with these infections. Additionally, Офтамирин is used as a preventive measure in the context of eye surgery or trauma to minimize the risk of developing secondary infections. It is important for individuals to consult with a qualified medical professional to determine if this therapy is appropriate for their specific clinical situation.

The official regulatory profile for Офтамирин (Ofatumumab) strictly defines population eligibility. Use is formally established only for adult patients 18 years of age and older.

The medicine is contraindicated and must not be used in individuals with an active Hepatitis B virus (HBV) infection, a history of severe hypersensitivity to the drug, or a severely immunocompromised state.

For certain populations, use is restricted or conditional:

• Pediatric Use: Safety and effectiveness are not yet established for individuals under 18 years of age.
• Pregnancy Status: Females of reproductive potential must use effective contraception during therapy and for at least six months following the final dose, as the drug may cause fetal harm.
• Comorbidity: Treatment must be delayed until any active infection has resolved. Patients with a history of HBV require mandatory pre-treatment screening, expert consultation, and ongoing monitoring.
• Organ Function: Use is not fully characterized in patients with renal or hepatic impairment, as dedicated pharmacokinetic studies in these groups are lacking.

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Офтамирин based strictly on regulatory prescribing information.

Documented Pharmacodynamic Interactions

The primary documented interactions involve local effects on the surface where the eye drops are applied, rather than systemic interactions throughout the body. These local interactions fall into two categories:

• Local Antagonism (Inactivation): The active ingredient of Офтамирин is chemically inactivated when used concurrently with, or immediately following the use of, anionic surfactants (including soap solutions). This interaction counteracts the intended effects of the medicine.

• Local Potentiation (Enhancement): Co-administration with local or systemic antibiotics results in the potentiation (enhancement) of the antibacterial and antifungal properties of the antibiotic agent itself. This effect is confined to the site of application.

Absence of Systemic Interactions and Formal Restrictions

Consistent with its classification as a topical agent with negligible systemic absorption, regulatory documents contain no statements regarding systemic drug interactions. Therefore, the official labeling includes the following:

Interaction Type	Status in Regulatory Labeling
Pharmacokinetic (CYP/Transporter)	None documented
Formal Contraindications	None documented for co-administered medicines
Food, Alcohol, Supplements	None documented
Timing Requirements	None documented

No medicinal products are formally designated in the official prescribing information as a contraindicated combination due to interaction risk.

How Офтамирин Works

Physical Lysis of Microbial Cell Membranes

The mechanism of action for Офтамирин (Myramistin) is defined by its role as a cationic surfactant, enacting a rapid, direct physico-chemical disruption of microbial structures. The drug's primary target is the microbial cell membrane, specifically the phospholipid bilayer found in bacteria, fungi, and lipid-enveloped viruses. The molecule's cationic charge facilitates immediate adsorption onto the negatively charged membrane surface, while its hydrophobic component disrupts the bilayer structure. This molecular cascade leads to the sudden loss of osmotic equilibrium within the pathogen, forcing the leakage of essential intracellular contents and resulting in quick cell lysis (destruction).

---

️ Mechanistic Confinement to the Application Site

Myramistin is characterized by strictly localized action, confining its potent lytic mechanism almost entirely to the ocular surface. Due to its size and high surface affinity, the molecule exhibits negligible systemic absorption. This results in local anti-infective activity confined to the application site, as the molecule's properties limit its systemic exposure. Conversely, this physical mechanism is subject to environmental antagonism when the surrounding fluid contains high concentrations of anionic proteins, which can competitively bind the molecule and diminish the rate of cell lysis.

Method of Application

The product is intended for topical use in the eyes, ears, or nose. When used for ophthalmic purposes, it is typically applied by instilling the solution into the conjunctival sac. For otolaryngological applications, the solution may be instilled into the nasal passages or the external auditory canal.

Handling and Preparation

To maintain the sterility of the solution, the tip of the dropper should not come into contact with the eye, eyelid, skin, or any other surfaces. Before use, the cap of the bottle is tightened to pierce the dropper tip if it is not already open. Following application, the cap should be replaced immediately and screwed on tightly.

Administration Techniques

• Ophthalmic Use: The head is tilted back slightly, and the lower eyelid is gently pulled down to create a small pocket. The solution is then applied according to the required frequency.
• Nasal or Otic Use: The solution is introduced into the nostril or the ear canal while maintaining a position that allows the liquid to remain in the affected area for a short period.

General Considerations

The duration of use and the frequency of application are determined based on the nature of the condition and the clinical response. If multiple topical medications are being used in the same area, a specific interval is usually maintained between applications to prevent the washout of the previous substance.

Research evidence / Overview of studies for Офтамирин

---

Evidence for Use in Superficial Ocular Infections

Research for Офтамирин (Myramistin Ophthalmic Solution) was studied for its potential application as a topical antiseptic for infections on the surface of the eye, such as acute bacterial conjunctivitis. Studies used in research exploring how symptoms change over time have included laboratory investigations (in vitro studies) to study the active ingredient's characteristics. Clinical studies, often localized and small-scale, were also applied in studies examining patient-reported experiences related to the infection.

Clinical studies evaluated short-term outcomes related to physical discomfort, such as the evolution of observable symptoms like redness and discharge. Studies also monitored microbiological outcomes, specifically assessing the presence of pathogenic microorganisms on the ocular surface. Findings describe patterns observed in the studies related to symptom patterns and how symptoms evolved in the observed populations during the short treatment periods. However, the evidence derived from settings with varying symptom burdens remains limited and is not consistently held to the same standards as large international trials.

---

Understanding the Study Design and Scope

The evidence base for Офтамирин was observed to have a specific geographic focus; a significant portion of the primary clinical research and evidence contributes to understanding symptom patterns, but originates from prior Soviet Bloc countries. This means that accessing complete details about the methodology and study design, which are required for comparison with international standards for randomized controlled trials (RCTs), may be challenging.

Research examined the medicine in clinical settings, and the resulting data show patterns related to what was observed, but robust comparative evidence is lacking in Western scientific literature. The existing research provides insight into short-term changes and focuses heavily on laboratory data that details the antimicrobial effects of the active ingredient. Research highlights changes measured during the study period concerning microbial presence, but sample sizes were modest in the clinical studies.

Common questions about Офтамирин (FAQ)

Q: What is the specific expiration period or 'use-by' time once the bottle of eye drops is first opened?

According to official product information and standard guidance for multi-dose eye preparations, the drops must be discarded after a specific period once the bottle is first opened. This period is often around 28 days to minimize the risk of bacterial contamination. Patients are typically advised to check the product label or consult a pharmacist for the exact 'in-use' shelf-life.

---

Q: What specific types of infections or eye conditions is Офтамирин used to treat according to the clinical evidence?

Regulatory documents define the specific approved conditions for which this medication is intended. These typically include the treatment of superficial ocular infections, such as acute bacterial conjunctivitis. The medicine may also be indicated for the prevention of infection associated with certain eye procedures.

---

Q: If I am pregnant or planning to be, what are the restrictions for using this medicine?

For the injectable form of this medication (Ofatumumab), official prescribing information indicates that the drug has the potential to cause harm to a fetus. For this reason, females who are able to become pregnant must use effective contraception while undergoing treatment and for a minimum of six months following the final dose.

---

Q: If I miss a monthly injection of the SC dose for RMS, what is the exact protocol for making up the dose?

Official administration guidelines for the subcutaneous dose state that a missed monthly dose should be administered as soon as possible. Subsequent maintenance doses are then typically administered one month from the date the missed dose was taken, as directed by a healthcare professional.

---

Q: How soon after I start the eye drops should I expect to see an improvement in my symptoms?

Studies and official information indicate that this type of topical antiseptic is used in short treatment courses, often evaluated over a period of 4 to 7 days. While clinical trials monitor the resolution of symptoms, individual results may vary. Patients are advised to consult their healthcare provider if they have concerns about symptom progression or expected timelines.

---

Q: Can I wear contact lenses while I am using Офтамирин eye drops?

The official product information must be checked for guidance regarding the use of contact lenses. A restriction may apply if the drops contain any inactive ingredients (excipients) that can be absorbed by soft contact lenses. Official guidance often instructs patients to remove lenses before application and wait a specified time before reinserting them.

---

Q: Does this drug contain any preservatives that could be harmful to the eye?

Regulatory documents list all components of a medicinal product. The official product information indicates that the formulation may be free of traditional ophthalmological preservatives since the active ingredient, Myramistin, functions as the primary antiseptic. Consult the full prescribing information for a complete list of ingredients.

Storage and Disposal Requirements

The official labeling for Офтамирин eye drops defines strict environmental and container constraints to maintain its sterility and efficacy. The medication must be kept out of the reach and sight of children at all times.

Storage Constraint	Requirement
Temperature	Store in a cool, dry place. Do not freeze the solution.
Container Integrity	Keep the bottle tightly closed to prevent contamination and store in its original container.
In-Use Stability	Discard the drops after the labeled in-use shelf-life is reached (e.g., typically 28 days after opening).

Disposal of unused or expired Офтамирин must follow regulatory guidance. The official instruction is to use a drug take-back program or designated collection point. It is explicitly prohibited to dispose of the product by pouring it down the drain or into surface water.